Yue Xiangyue Health | June 2026 Monthly Update
Barty Medical
Vascular Interventional and Implantable Device R&D Manufacturer
Vivolight
Developer of Biomedical Optical Imaging Systems
Highlightll Pharma
Innovative Drug Developer
Trinomab
Developer of Natural Fully Human Monoclonal Antibody New Drugs
SPH
Pharmaceutical R&D and Manufacturing
Atom Therapeutics
Innovative Drug Developer
Click to Follow | Focused on Global Biopharma Investment
On June 10, 2026, "Shenzhen Yifeng Mingyuan Seed Venture Capital Partnership (Limited Partnership)," established with equity participation from the Shenzhen Science and Technology Innovation Seed Fund, officially completed its industrial and commercial registration, marking a critical step for Yifeng Capital in its strategic layout of ultra-early-stage investments.
Notably, this month has seen a surge of positive developments within the portfolio ecosystem of Yifeng Capital, with multiple investee companies achieving breakthroughs in advancing their financing rounds and expanding core businesses. The overall investment ecosystem is rapidly entering a phase of tangible returns.
West Lake Bio
· Westlake Biology Completes Over RMB 100 Million in Financing
Xihu Biology Announces Completion of New Strategic Financing Round Exceeding RMB 100 Million; Yifeng Capital, as an Existing Shareholder, Continues to Increase Investment.
Carbon Creates All Things
· Carbon Life Completes Series A Financing
Tansheng Wanwu Completes Series A FinancingRecently, Tansheng Wanwu completed its Series A financing round. The round was invested by institutions including Yifeng Capital and Boyuan Capital.
Barty Medical
· Barty Medical Completes Nearly RMB 200 Million in Series D Financing
Barty Medical Completes Nearly RMB 200 Million in Series D Financing, Accelerating the Commercialization and Globalization of Innovative Pan-vascular Interventional Devices
Ruijia Kang
· Ruijiakang Secures Additional Funding
Recently, Wuhan Ruijiakang secured Series B financing from Yifeng Zhuohua Fund. The funds raised in this round will be primarily used for the “Demonstration Base for Non-Grain Biological Manufacturing of 10,000-Ton-Level Bio-Based Platform Compounds” project.
Vivolight
· Completed Hundreds of Millions in Financing
Vivolight Completes New Round of Financing Amounting to Hundreds of Millions of Yuan, Co-led by China-US Green Yangtze River Delta and Yifeng Capital
Highlightll Pharma
· Highlightll Pharma Files for HK IPO
On June 8, the Hong Kong Stock Exchange’s official website showed that Highlightll Pharma submitted an IPO application.
West Lake Bio
· Westlake Biology Completes Over RMB 100 Million in Financing
West Lake Bio
· Westlake Biology Completes Over RMB 100 Million in Financing
Xihu Biology Announces Completion of New Strategic Financing Round Exceeding RMB 100 Million; Yifeng Capital, as an Existing Shareholder, Continues to Increase Investment.
Carbon Creates All Things
· Carbon Life Completes Series A Financing
Carbon Creates All Things
· Carbon Life Completes Series A Financing
Tansheng Wanwu Completes Series A FinancingRecently, Tansheng Wanwu completed its Series A financing round. The round was invested by institutions including Yifeng Capital and Boyuan Capital.
Barty Medical
· Barty Medical Completes Nearly RMB 200 Million in Series D Financing
Barty Medical
· Barty Medical Completes Nearly RMB 200 Million in Series D Financing
Barty Medical Completes Nearly RMB 200 Million in Series D Financing, Accelerating the Commercialization and Globalization of Innovative Pan-vascular Interventional Devices
Ruijia Kang
· Ruijiakang Secures Additional Funding
Ruijia Kang
· Ruijiakang Secures Additional Funding
Recently, Wuhan Ruijiakang secured Series B financing from Yifeng Zhuohua Fund. The funds raised in this round will be primarily used for the “Demonstration Base for Non-Grain Biological Manufacturing of 10,000-Ton-Level Bio-Based Platform Compounds” project.
Vivolight
· Completed Hundreds of Millions in Financing
Vivolight
· Completed Hundreds of Millions in Financing
Vivolight Completes New Round of Financing Amounting to Hundreds of Millions of Yuan, Co-led by China-US Green Yangtze River Delta and Yifeng Capital
Highlightll Pharma
· Highlightll Pharma Files for HK IPO
Highlightll Pharma
· Highlightll Pharma Files for HK IPO
On June 8, the Hong Kong Stock Exchange’s official website showed that Highlightll Pharma submitted an IPO application.
Highlightll Pharma
· JAK1/TYK2 Proposed for Breakthrough Therapy Designation
Highlightll Pharma
· JAK1/TYK2 Proposed for Breakthrough Therapy Designation
Highlightll Pharma
· JAK1/TYK2 Proposed for Breakthrough Therapy Designation
On June 24, 2026, Highlightll Pharma’s JAK1/TYK2 inhibitor TLL-018 tablets were proposed for inclusion in the Breakthrough Therapy Designation program for the treatment of rheumatoid arthritis.
Trinomab
· Partnering with SPH to Accelerate the Global Expansion of Stedumab, a Next-Generation "Tetanus Shot"
Trinomab
· Partnering with SPH to Accelerate the Global Expansion of Stedumab, a Next-Generation "Tetanus Shot"
Recently, Trinomab and the International Business Division of SPH held a signing ceremony in Shanghai for the strategic cooperation on the commercialization of Staidumab in the Philippines.
Huayuan Regeneration
· Attending ISO 2026: Discussing Frontier Explorations in the Treatment of Kidney Diseases
Huayuan Regeneration
· Attending ISO 2026: Discussing Frontier Explorations in the Treatment of Kidney Diseases
June 11–12, ISO 2026 Fifth In-Depth Focus Forum on Stem Cell Therapy and Organoids was held in Beijing.Dr. Liu Yajing, Vice President of Regenerative Cell R&D at Huayuan, participated extensively in the sub-forum on “Development of iPSC-Derived Stem Cell Therapies.”
Kentuo Fluid
· The New MAP96 Pipette Series Has Arrived
June 11–12, ISO 2026 Fifth In-Depth Focus Forum on Stem Cell Therapy and Organoids was held in Beijing.Dr. Liu Yajing, Vice President of Regenerative Cell R&D at Huayuan, participated extensively in the sub-forum on “Development of iPSC-Derived Stem Cell Therapies.”
June 11–12, ISO 2026 Fifth In-Depth Focus Forum on Stem Cell Therapy and Organoids was held in Beijing.Dr. Liu Yajing, Vice President of Regenerative Cell R&D at Huayuan, participated extensively in the sub-forum on “Development of iPSC-Derived Stem Cell Therapies.”
Kentuo Fluid
· The New MAP96 Pipette Series Has Arrived
Kentuo Fluid
· The New MAP96 Pipette Series Has Arrived
Recently, the new version of Kentuo MAP96 pipette has been launched.
Atom Therapeutics
· New Anti-Gout Drug Launches Phase III Clinical Trial in China
Atom Therapeutics
· New Anti-Gout Drug Launches Phase III Clinical Trial in China
Atom Therapeutics
· New Anti-Gout Drug Launches Phase III Clinical Trial in China
Atom Therapeutics
· New Anti-Gout Drug Launches Phase III Clinical Trial in China
On June 23, Atom Therapeutics announced that its independently developed innovative small-molecule drug for gout, ABP-671 (lingdolinurad), has initiated Phase III clinical trials in China, with the first patient enrolled and dosed.
KeNing Bio
· Launch of the First-in-Human Clinical Trial for Dry Eye Disease
KeNing Bio
· Launch of the First-in-Human Clinical Trial for Dry Eye Disease
KeNing Bio
· Launch of the First-in-Human Clinical Trial for Dry Eye Disease
Recently, Kening Biologics announced that the first subject in its first-in-human (FIH) clinical trial for dry eye disease has completed dosing.
Huamei Haolian
· Invited to Attend the AI+ Empowering Alumni Development Forum
Huamei Haolian
· Invited to Attend the AI+ Empowering Alumni Development Forum
Huamei Haolian
· Invited to Attend the AI+ Empowering Alumni Development Forum
Recently, Huamei Haolian was invited to attend the AI+ Empowering Alumni Development Forum, where it discussed how AI-driven health management is reshaping the value chain of the medical ecosystem.
· Featured at the HKU Business School Forum
On the afternoon of June 13, the themed forum “Smart Innovation in Healthcare, Prosperity and Public Health” was held in Hong Kong. Xu Bingyu, Founder and CEO of Huamei Haolian, attended the event and delivered a keynote speech.
· Featured at the HKU Business School Forum
On the afternoon of June 13, the themed forum “Smart Innovation in Healthcare, Prosperity and Public Health” was held in Hong Kong. Xu Bingyu, Founder and CEO of Huamei Haolian, attended the event and delivered a keynote speech.
Tianqin Bio
· Tianqin Bio's NHP Metabolic Model Debuts at the ADA Annual Meeting
Tianqin Bio
· Tianqin Bio's NHP Metabolic Model Debuts at the ADA Annual Meeting
Tianqin Bio
· Tianqin Bio's NHP Metabolic Model Debuts at the ADA Annual Meeting
Recently, at the 86th American Diabetes Association (ADA) Scientific Sessions held in New Orleans, USA, Tianqin Bio’s independently developed non-human primate (NHP) models of metabolic diseases attracted widespread attention.
· Facilitating the Clinical Trial Approval of Mabwell's Innovative Drug 9MW5211
Recently, Mabwell announced that the Investigational New Drug (IND) application for its innovative drug 9MW5211 has officially been approved by the U.S. Food and Drug Administration (FDA). Tianqin Xinsheng, a wholly-owned subsidiary of Tianqin Bio, provided comprehensive toxicology research services for this project.
Hannuo Medical
· Building a Global ECMO Expert Platform
Hannuo Medical
· Building a Global ECMO Expert Platform
From June 11 to 13, the 8th Annual Conference of the Asia-Pacific Extracorporeal Life Support Organization was held in Japan. Hanuo Medical prominently showcased the multi-mode conversion capabilities of its Lifemotion ECMO system at the exhibition.
Lingyi Bio
· Debut at the 3rd International GBA1 Conference
Lingyi Bio
· Debut at the 3rd International GBA1 Conference
Lingyi Bio Makes Debut at the 3rd International GBA1 Conference, Showcasing Latest Advances in Gene Therapy Research for GBA1-Related Parkinson’s Disease
Jingwei Shida
· Debut at the 23rd Beijing International Digestive Disease Forum
Jingwei Shida
· Debut at the 23rd Beijing International Digestive Disease Forum
Jingwei Shida
· Debut at the 23rd Beijing International Digestive Disease Forum
On June 14, the 2026 World Chinese Gastroenterologists Annual Conference and the 23rd Beijing International Digestive Disease Forum concluded in Beijing. Jingwei Shida joined forces with clinical experts to explore new pathways for the standardized and precise development of digestive endoscopy, focusing on multiple dimensions including the construction of the WEO-ERCP training system.
Zifu Medical
· Debut at the 2026 Hangzhou Endoscopy Conference
On June 4, the 3rd Conference on Medical Endoscopy Technology Development and the 1st Medical Surgical Robot Forum were held in Hangzhou. Zifu Medical was invited to attend the conference and delivered a keynote presentation.
Zifu Medical
· Debut at the 2026 Hangzhou Endoscopy Conference
On June 4, the 3rd Conference on Medical Endoscopy Technology Development and the 1st Medical Surgical Robot Forum were held in Hangzhou. Zifu Medical was invited to attend the conference and delivered a keynote presentation.
Real Biotech
· Featured at the ASCO Annual Meeting
Recently, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in the United States. ZhenShi Bio, in collaboration with Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, presented the Phase I clinical study data of Azvudine in patients with advanced solid tumors in the form of a poster.
Tiangan Medino
· Debut at the 2026 BIO International Convention
From June 22 to 25, Tiangang Yinnuo made its debut at the 2026 BIO International Convention in the United States, where Dr. Yin Liusong, Chief Scientific Officer, delivered a public presentation.
Pinshan Biotech
· Signed a strategic cooperation agreement with Ripley Jin
Recently, Pinshan Biotech and Repligen officially signed a strategic cooperation agreement, announcing in-depth collaboration in the field of hollow fiber filter products.
Saiyuan Biotech
· Partnering with Walvax to Accelerate Clinical Research on in vivo CAR Immune Cell Therapy
Recently, Saiyuan Biotechnology and Walvax Biotechnology officially signed a project collaboration and development agreement. The two parties will focus on in vivo CAR therapies based on the mRNA-LNP technology platform and jointly advance investigator-initiated trials (IIT) for the treatment of hepatocellular carcinoma solid tumors.
· Featured at the 2026 ASCO Annual Meeting
Recently, the founding team of Saiyuan Bioscience presented two latest research reports on tumor immune cell therapy at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, USA.
Ailios
· Shining at CPHI China 2026
From June 16 to 18, the 24th World Pharmaceutical Raw Materials China Exhibition was held in Shanghai. Ailios showcased its comprehensive end-to-end filtration solutions, covering depth filtration, liquid pre-filtration, sterilizing-grade filtration, and hardware systems.
Newrite
· Debut at Top Academic Platform in Asia-Pacific
From June 11 to 14, the 20th Asia-Pacific Academic Conference on Cardiovascular and Interventional Radiology was held in Suzhou. Neurate Medical systematically showcased its forward-looking layout and key technological achievements in the field of interventional radiology and nuclear medicine at this conference.
Carbon Creates All Things
· Ningdong 1,000-Ton e-SAF Project Commences Construction
On June 16, the Carbon-to-Everything 1,000-ton Direct Air Capture (DAC) Project for Producing Sustainable Aviation Fuel (e-SAF) officially commenced construction at the Ningdong Energy and Chemical Industry Base in Ningxia.
Bokang Shiyun
· Global innovative ophthalmic drug CBT-001 completes enrollment of all patients in its international multicenter Phase III clinical trial
Recently, BoKang Vision Cloud announced that the international multicenter Phase III clinical trial of CBT-001, a globally innovative ophthalmic drug in its pipeline for the treatment of pterygium, has completed the enrollment of all patients at global sites.
WuYuan Biologics
· On-Site Coverage of the Technology Empowerment Sub-Forum at the Annual Conference of Chinese Hospital Presidents
From June 5 to 7, the 20th Annual Conference of Chinese Hospital Presidents was grandly held at the Xiamen International Expo & Convention Center. Huiyuan Biotech showcased Aofumin® at the “Technology Empowerment” sub-forum.
Huahao Zhongtian
· Debut at the 2026 ASCO Annual Meeting
Recently, the American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. Huahao Zhongtian announced the final data from its Phase II clinical study evaluating the core product, utidelone capsules, in combination with capecitabine (CAP) for the treatment of metastatic breast cancer.Latest Clinical Study on the UTD1 (Utidelone Injection) Combination Regimen for the Treatment of HER2-Positive Metastatic Breast Cancer, Latest data from the FRUTD-001 study.
Real Biotech
· Featured at the ASCO Annual Meeting
Recently, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in the United States. ZhenShi Bio, in collaboration with Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, presented the Phase I clinical study data of Azvudine in patients with advanced solid tumors in the form of a poster.
Real Biotech
· Featured at the ASCO Annual Meeting
Recently, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in the United States. ZhenShi Bio, in collaboration with Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, presented the Phase I clinical study data of Azvudine in patients with advanced solid tumors in the form of a poster.
Tiangan Medino
· Debut at the 2026 BIO International Convention
From June 22 to 25, Tiangang Yinnuo made its debut at the 2026 BIO International Convention in the United States, where Dr. Yin Liusong, Chief Scientific Officer, delivered a public presentation.
Tiangan Medino
· Debut at the 2026 BIO International Convention
From June 22 to 25, Tiangang Yinnuo made its debut at the 2026 BIO International Convention in the United States, where Dr. Yin Liusong, Chief Scientific Officer, delivered a public presentation.
Pinshan Biotech
· Signed a strategic cooperation agreement with Ripley Jin
Recently, Pinshan Biotech and Repligen officially signed a strategic cooperation agreement, announcing in-depth collaboration in the field of hollow fiber filter products.
Pinshan Biotech
· Signed a strategic cooperation agreement with Ripley Jin
Recently, Pinshan Biotech and Repligen officially signed a strategic cooperation agreement, announcing in-depth collaboration in the field of hollow fiber filter products.
Saiyuan Biotech
· Partnering with Walvax to Accelerate Clinical Research on in vivo CAR Immune Cell Therapy
Recently, Saiyuan Biotechnology and Walvax Biotechnology officially signed a project collaboration and development agreement. The two parties will focus on in vivo CAR therapies based on the mRNA-LNP technology platform and jointly advance investigator-initiated trials (IIT) for the treatment of hepatocellular carcinoma solid tumors.
· Featured at the 2026 ASCO Annual Meeting
Recently, the founding team of Saiyuan Bioscience presented two latest research reports on tumor immune cell therapy at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, USA.
Saiyuan Biotech
· Partnering with Walvax to Accelerate Clinical Research on in vivo CAR Immune Cell Therapy
Recently, Saiyuan Biotechnology and Walvax Biotechnology officially signed a project collaboration and development agreement. The two parties will focus on in vivo CAR therapies based on the mRNA-LNP technology platform and jointly advance investigator-initiated trials (IIT) for the treatment of hepatocellular carcinoma solid tumors.
· Featured at the 2026 ASCO Annual Meeting
Recently, the founding team of Saiyuan Bioscience presented two latest research reports on tumor immune cell therapy at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, USA.
Ailios
· Shining at CPHI China 2026
From June 16 to 18, the 24th World Pharmaceutical Raw Materials China Exhibition was held in Shanghai. Ailios showcased its comprehensive end-to-end filtration solutions, covering depth filtration, liquid pre-filtration, sterilizing-grade filtration, and hardware systems.
Ailios
· Shining at CPHI China 2026
From June 16 to 18, the 24th World Pharmaceutical Raw Materials China Exhibition was held in Shanghai. Ailios showcased its comprehensive end-to-end filtration solutions, covering depth filtration, liquid pre-filtration, sterilizing-grade filtration, and hardware systems.
Newrite
· Debut at Top Academic Platform in Asia-Pacific
From June 11 to 14, the 20th Asia-Pacific Academic Conference on Cardiovascular and Interventional Radiology was held in Suzhou. Neurate Medical systematically showcased its forward-looking layout and key technological achievements in the field of interventional radiology and nuclear medicine at this conference.
Newrite
· Debut at Top Academic Platform in Asia-Pacific
From June 11 to 14, the 20th Asia-Pacific Academic Conference on Cardiovascular and Interventional Radiology was held in Suzhou. Neurate Medical systematically showcased its forward-looking layout and key technological achievements in the field of interventional radiology and nuclear medicine at this conference.
Carbon Creates All Things
· Ningdong 1,000-Ton e-SAF Project Commences Construction
On June 16, the Carbon-to-Everything 1,000-ton Direct Air Capture (DAC) Project for Producing Sustainable Aviation Fuel (e-SAF) officially commenced construction at the Ningdong Energy and Chemical Industry Base in Ningxia.
Bokang Shiyun
· Global innovative ophthalmic drug CBT-001 completes enrollment of all patients in its international multicenter Phase III clinical trial
Recently, BoKang Vision Cloud announced that the international multicenter Phase III clinical trial of CBT-001, a globally innovative ophthalmic drug in its pipeline for the treatment of pterygium, has completed the enrollment of all patients at global sites.
Carbon Creates All Things
· Ningdong 1,000-Ton e-SAF Project Commences Construction
On June 16, the Carbon-to-Everything 1,000-ton Direct Air Capture (DAC) Project for Producing Sustainable Aviation Fuel (e-SAF) officially commenced construction at the Ningdong Energy and Chemical Industry Base in Ningxia.
Bokang Shiyun
· Global innovative ophthalmic drug CBT-001 completes enrollment of all patients in its international multicenter Phase III clinical trial
Recently, BoKang Vision Cloud announced that the international multicenter Phase III clinical trial of CBT-001, a globally innovative ophthalmic drug in its pipeline for the treatment of pterygium, has completed the enrollment of all patients at global sites.
WuYuan Biologics
· On-Site Coverage of the Technology Empowerment Sub-Forum at the Annual Conference of Chinese Hospital Presidents
WuYuan Biologics
· On-Site Coverage of the Technology Empowerment Sub-Forum at the Annual Conference of Chinese Hospital Presidents
WuYuan Biologics
· On-Site Coverage of the Technology Empowerment Sub-Forum at the Annual Conference of Chinese Hospital Presidents
From June 5 to 7, the 20th Annual Conference of Chinese Hospital Presidents was grandly held at the Xiamen International Expo & Convention Center. Huiyuan Biotech showcased Aofumin® at the “Technology Empowerment” sub-forum.
Huahao Zhongtian
· Debut at the 2026 ASCO Annual Meeting
Recently, the American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. Huahao Zhongtian announced the final data from its Phase II clinical study evaluating the core product, utidelone capsules, in combination with capecitabine (CAP) for the treatment of metastatic breast cancer.Latest Clinical Study on the UTD1 (Utidelone Injection) Combination Regimen for the Treatment of HER2-Positive Metastatic Breast Cancer, Latest data from the FRUTD-001 study.
Huahao Zhongtian
· Debut at the 2026 ASCO Annual Meeting
Recently, the American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. Huahao Zhongtian announced the final data from its Phase II clinical study evaluating the core product, utidelone capsules, in combination with capecitabine (CAP) for the treatment of metastatic breast cancer.Latest Clinical Study on the UTD1 (Utidelone Injection) Combination Regimen for the Treatment of HER2-Positive Metastatic Breast Cancer, Latest data from the FRUTD-001 study.
Huahao Zhongtian
· Debut at the 2026 ASCO Annual Meeting
Recently, the American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. Huahao Zhongtian announced the final data from its Phase II clinical study evaluating the core product, utidelone capsules, in combination with capecitabine (CAP) for the treatment of metastatic breast cancer.Latest Clinical Study on the UTD1 (Utidelone Injection) Combination Regimen for the Treatment of HER2-Positive Metastatic Breast Cancer, Latest data from the FRUTD-001 study.
Huahao Zhongtian
· Debut at the 2026 ASCO Annual Meeting
Recently, the American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago. Huahao Zhongtian announced the final data from its Phase II clinical study evaluating the core product, utidelone capsules, in combination with capecitabine (CAP) for the treatment of metastatic breast cancer.Latest Clinical Study on the UTD1 (Utidelone Injection) Combination Regimen for the Treatment of HER2-Positive Metastatic Breast Cancer, Latest data from the FRUTD-001 study.
Pulai Pharma
· World’s First Cannabinoid-like Antimicrobial Peptide New Drug Approved for Market Launch
On June 17, Puyi Pharmaceutical’s independently developed Puyike®, China’s first Class 1 innovative drug in the canin antimicrobial peptide category, received marketing approval from the National Medical Products Administration (NMPA).
Ruijing Biotech
· NGS Molecular Diagnostic Kit for Thyroid Cancer Officially Approved
On June 23, Ruijing Biologics’ independently developed “Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit” received Class III medical device registration certification from the National Medical Products Administration (NMPA). It is the first and only approved molecular diagnostic kit for thyroid cancer on a next-generation sequencing (NGS) platform in China.
Huahao Zhongtian
· The World's First Oral Solid Microtubule StabilizerIIIPhase Clinical Trial Approved
On June 11, Huahao Zhongtian announced that its core investigational product, Utidelone Capsules (UTD2), had received clinical trial approval from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III study in the treatment of HER2-negative advanced breast cancer.
Vivolight
· Domestically Developed Original 355nm Cold Laser Ablation Device Approved for Market Launch
Recently, FastErazer, a triple-frequency Nd:YAG laser ablation device independently developed by Vivolight’s subsidiary Zhongke Rongguang, has officially received market approval from the National Medical Products Administration.
Tingsheng Technology
· No.7AmountICEProductTINGSN Sonic Eyes 8 Pro Approved
On June 23, Tingsn Technology’s TINGSN Sonic Eyes 8 Pro disposable intracardiac echocardiography diagnostic catheter officially received approval from the National Medical Products Administration (NMPA), successfully obtaining a Class III medical device registration certificate.
Xuanyu Medical
· StrenSoft™ Adjustable-Curved Pulmonary Artery Embolectomy Stent System Officially ApprovedNMPA
On June 1, the StrenSoft™ Adjustable-Curve Pulmonary Artery Embolectomy Stent System, independently developed by Xuanyu Medical, officially received market approval from the National Medical Products Administration (NMPA).
Triluk Biologics
· New Drug Application for Yiqiolun Injection Officially Approved by Singapore Health Sciences Authority
On June 18, Reindeer Biotech announced that the Health Sciences Authority (HSA) of Singapore had officially approved its New Drug Application for market authorization of Ikiocel Injection, a fully human anti-BCMA CAR-T cell therapy product independently developed by the company.
Pulai Pharma
· World’s First Cannabinoid-like Antimicrobial Peptide New Drug Approved for Market Launch
On June 17, Puyi Pharmaceutical’s independently developed Puyike®, China’s first Class 1 innovative drug in the canin antimicrobial peptide category, received marketing approval from the National Medical Products Administration (NMPA).
Ruijing Biotech
· NGS Molecular Diagnostic Kit for Thyroid Cancer Officially Approved
On June 23, Ruijing Biologics’ independently developed “Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit” received Class III medical device registration certification from the National Medical Products Administration (NMPA). It is the first and only approved molecular diagnostic kit for thyroid cancer on a next-generation sequencing (NGS) platform in China.
Huahao Zhongtian
· The World's First Oral Solid Microtubule StabilizerIIIPhase Clinical Trial Approved
On June 11, Huahao Zhongtian announced that its core investigational product, Utidelone Capsules (UTD2), had received clinical trial approval from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III study in the treatment of HER2-negative advanced breast cancer.
Vivolight
· Domestically Developed Original 355nm Cold Laser Ablation Device Approved for Market Launch
Recently, FastErazer, a triple-frequency Nd:YAG laser ablation device independently developed by Vivolight’s subsidiary Zhongke Rongguang, has officially received market approval from the National Medical Products Administration.
Tingsheng Technology
· No.7AmountICEProductTINGSN Sonic Eyes 8 Pro Approved
On June 23, Tingsn Technology’s TINGSN Sonic Eyes 8 Pro disposable intracardiac echocardiography diagnostic catheter officially received approval from the National Medical Products Administration (NMPA), successfully obtaining a Class III medical device registration certificate.
Xuanyu Medical
· StrenSoft™ Adjustable-Curved Pulmonary Artery Embolectomy Stent System Officially ApprovedNMPA
On June 1, the StrenSoft™ Adjustable-Curve Pulmonary Artery Embolectomy Stent System, independently developed by Xuanyu Medical, officially received market approval from the National Medical Products Administration (NMPA).
Triluk Biologics
· New Drug Application for Yiqiolun Injection Officially Approved by Singapore Health Sciences Authority
On June 18, Reindeer Biotech announced that the Health Sciences Authority (HSA) of Singapore had officially approved its New Drug Application for market authorization of Ikiocel Injection, a fully human anti-BCMA CAR-T cell therapy product independently developed by the company.
Pulai Pharma
· World’s First Cannabinoid-like Antimicrobial Peptide New Drug Approved for Market Launch
On June 17, Puyi Pharmaceutical’s independently developed Puyike®, China’s first Class 1 innovative drug in the canin antimicrobial peptide category, received marketing approval from the National Medical Products Administration (NMPA).
Pulai Pharma
· World’s First Cannabinoid-like Antimicrobial Peptide New Drug Approved for Market Launch
On June 17, Puyi Pharmaceutical’s independently developed Puyike®, China’s first Class 1 innovative drug in the canin antimicrobial peptide category, received marketing approval from the National Medical Products Administration (NMPA).
Pulai Pharma
· World’s First Cannabinoid-like Antimicrobial Peptide New Drug Approved for Market Launch
On June 17, Puyi Pharmaceutical’s independently developed Puyike®, China’s first Class 1 innovative drug in the canin antimicrobial peptide category, received marketing approval from the National Medical Products Administration (NMPA).
Ruijing Biotech
· NGS Molecular Diagnostic Kit for Thyroid Cancer Officially Approved
On June 23, Ruijing Biologics’ independently developed “Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit” received Class III medical device registration certification from the National Medical Products Administration (NMPA). It is the first and only approved molecular diagnostic kit for thyroid cancer on a next-generation sequencing (NGS) platform in China.
Huahao Zhongtian
· The World's First Oral Solid Microtubule StabilizerIIIPhase Clinical Trial Approved
On June 11, Huahao Zhongtian announced that its core investigational product, Utidelone Capsules (UTD2), had received clinical trial approval from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III study in the treatment of HER2-negative advanced breast cancer.
Ruijing Biotech
· NGS Molecular Diagnostic Kit for Thyroid Cancer Officially Approved
On June 23, Ruijing Biologics’ independently developed “Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit” received Class III medical device registration certification from the National Medical Products Administration (NMPA). It is the first and only approved molecular diagnostic kit for thyroid cancer on a next-generation sequencing (NGS) platform in China.
Huahao Zhongtian
· The World's First Oral Solid Microtubule StabilizerIIIPhase Clinical Trial Approved
On June 11, Huahao Zhongtian announced that its core investigational product, Utidelone Capsules (UTD2), had received clinical trial approval from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III study in the treatment of HER2-negative advanced breast cancer.
Ruijing Biotech
· NGS Molecular Diagnostic Kit for Thyroid Cancer Officially Approved
On June 23, Ruijing Biologics’ independently developed “Human BRAF/TERT/RET/NTRK3 Gene Mutation Detection Kit” received Class III medical device registration certification from the National Medical Products Administration (NMPA). It is the first and only approved molecular diagnostic kit for thyroid cancer on a next-generation sequencing (NGS) platform in China.
Huahao Zhongtian
· The World's First Oral Solid Microtubule StabilizerIIIPhase Clinical Trial Approved
On June 11, Huahao Zhongtian announced that its core investigational product, Utidelone Capsules (UTD2), had received clinical trial approval from the National Medical Products Administration (NMPA) for a randomized, controlled Phase III study in the treatment of HER2-negative advanced breast cancer.
Vivolight
· Domestically Developed Original 355nm Cold Laser Ablation Device Approved for Market Launch
Recently, FastErazer, a triple-frequency Nd:YAG laser ablation device independently developed by Vivolight’s subsidiary Zhongke Rongguang, has officially received market approval from the National Medical Products Administration.
Tingsheng Technology
· No.7AmountICEProductTINGSN Sonic Eyes 8 Pro Approved
On June 23, Tingsn Technology’s TINGSN Sonic Eyes 8 Pro disposable intracardiac echocardiography diagnostic catheter officially received approval from the National Medical Products Administration (NMPA), successfully obtaining a Class III medical device registration certificate.
Xuanyu Medical
· StrenSoft™ Adjustable-Curved Pulmonary Artery Embolectomy Stent System Officially ApprovedNMPA
On June 1, the StrenSoft™ Adjustable-Curve Pulmonary Artery Embolectomy Stent System, independently developed by Xuanyu Medical, officially received market approval from the National Medical Products Administration (NMPA).
Triluk Biologics
· New Drug Application for Yiqiolun Injection Officially Approved by Singapore Health Sciences Authority
On June 18, Reindeer Biotech announced that the Health Sciences Authority (HSA) of Singapore had officially approved its New Drug Application for market authorization of Ikiocel Injection, a fully human anti-BCMA CAR-T cell therapy product independently developed by the company.
Approved to Establish a Branch Station for Postdoctoral Research
Won the 2026 Global MedTech "Ophthalmic Innovative Device Award"
· Century Kangtai
Achieved a perfect score in the National Center for Clinical Laboratories (NCCL) of the National Health Commission – 2026 Pilot External Quality Assessment Program for High-Throughput Sequencing Detection of Solid Tumor Fusion Genes (RNA Level)
· Maijing Gene
Won the "Jiutian Lanyue Award" at the Molecular Laboratory - 2026 Annual Insurance Technology Innovation Competition
· Huamei Haolian
Won E-Pharm Manager - 2026 Top 100 Chinese Pharmaceutical Innovation Enterprises
· Ascentage Pharma, Tiangang Yinuo
Recognized as a Hangzhou “Good Seedling” Enterprise
· Westlake Omics
Honored as the Head of the Artificial Intelligence Department of the 4th Executive Committee of CCI
· Zhu Rui, Chairman of Vivolight
Ranked Among the Top 100 in Chemical Drug R&D Strength in 2026
· Beta Pharma
Honored as One of the Top 100 Seed Enterprises in China’s Pharmaceutical Innovation for 2026
· Highlightll Pharma
Approved to Establish a Branch Station for Postdoctoral Research
Won the 2026 Global MedTech "Ophthalmic Innovative Device Award"
· Century Kangtai
Achieved a perfect score in the National Center for Clinical Laboratories (NCCL) of the National Health Commission – 2026 Pilot External Quality Assessment Program for High-Throughput Sequencing Detection of Solid Tumor Fusion Genes (RNA Level)
· Maijing Gene
Won the "Jiutian Lanyue Award" at the Molecular Laboratory - 2026 Annual Insurance Technology Innovation Competition
· Huamei Haolian
Won E-Pharm Manager - 2026 Top 100 Chinese Pharmaceutical Innovation Enterprises
· Ascentage Pharma, Tiangang Yinuo
Recognized as a Hangzhou “Good Seedling” Enterprise
· Westlake Omics
Honored as the Head of the Artificial Intelligence Department of the 4th Executive Committee of CCI
· Zhu Rui, Chairman of Vivolight
Ranked Among the Top 100 in Chemical Drug R&D Strength in 2026
· Beta Pharma
Honored as One of the Top 100 Seed Enterprises in China’s Pharmaceutical Innovation for 2026
· Highlightll Pharma
Yifeng Capital
Venture Capital Firms in China's Private Equity Industry
Zhu Pai, CEO of Yifeng Capital
2026 China's Best Young Investment Figures
Yifeng Mingyuan Seed Fund Lands in Guangming
· On June 10, Shenzhen Yifeng Mingyuan Seed Venture Capital Partnership (Limited Partnership), established with participation from the Shenzhen Science and Technology Innovation Seed Fund, officially completed its industrial and commercial registration. This marks a critical step forward for Yifeng Capital in its strategic layout for ultra-early-stage investments.
Multiple Portfolio Companies of Yifeng Capital Present Breakthrough Data at ASCO 2026
·June 2, AnnualThe world’s premier academic conference in oncology—the American Society of Clinical Oncology (ASCO) Annual Meeting—concluded in the United States. Portfolio companies of Yifeng Capital, including Westlake University Biopharma, Zhenshi Biopharma, Qiyu Biopharma, Huahao Zhongtian, Saiyuan Biopharma, Ascentage Pharma, and Chipscreen Biosciences, presented significant clinical research findings.
✦
Recommended Reading
✦
NorthLife's IPO on the STAR Market
✦
Recommended Reading
✦
NorthLife's IPO on the STAR Market
NorthLife's IPO on the STAR Market
Wuhan HealthGene Biotech's IPO on the STAR Market
Bokang Shiyun's IPO on the Main Board of the Hong Kong Stock Exchange
Shenghe Biotech's IPO on the Main Board of the Hong Kong Stock Exchange
Quanxin Biologics' IPO on the Main Board of the Hong Kong Stock Exchange
Swimming Against the Current, Moving Forward with Time
3D Medicines Hong Kong Main Board IPO
GenePharma's STAR Market IPO
Ten Years Honing the Sword, Unsheathed with Sharp Edge
Yahong Medicine's STAR Market IPO
Looking forward to your
Share
Like
Watching
Wuhan HealthGene Biotech's IPO on the STAR Market
Wuhan HealthGene Biotech's IPO on the STAR Market
Wuhan HealthGene Biotech's IPO on the STAR Market
Bokang Shiyun's IPO on the Main Board of the Hong Kong Stock Exchange
Bokang Shiyun's IPO on the Main Board of the Hong Kong Stock Exchange
Shenghe Biotech's IPO on the Main Board of the Hong Kong Stock Exchange
Quanxin Biologics' IPO on the Main Board of the Hong Kong Stock Exchange
Swimming Against the Current, Moving Forward with Time
3D Medicines Hong Kong Main Board IPO
GenePharma's STAR Market IPO
Ten Years Honing the Sword, Unsheathed with Sharp Edge
Yahong Medicine's STAR Market IPO
Looking forward to your
Share
Like
Watching